Venture capital arm of “la Caixa”, that invests in innovative SMEs in the early phases. Caixa Capital Risc currently manages nearly €200 million through eight investment vehicles and has a portfolio of 195 companies. It is a multisector investor that focuses mainly on emerging sectors: technology, digital industry, industrial technology and the life sciences. In addition to its investment activity, Caixa Capital Risc also carries out programmes to promote the transfer of research and to guide innovative enterprises and projects with high potential for growth.
Venture capital fund that invests in companies in the early stages of development in the healthcare sector, focusing mainly on biotechnology and medical devices. Founded by the Barcelona Medical Association and the Riva y García financial group, HealthEquity looks for projects at companies in the health sciences sector to develop on the market, as well as helping foster the Catalan and Spanish biotechnology ecosystem.
This project has received funding from the European Union’s Horizon 2020 (SME Instrument) research and innovation programme under Grant Agreements:
Phase 1: No. 826930
Phase 2: No. 849047
This project has received funding from the EIT Health’s Headstart Funding Programme 2018, has been selected as semi-finalist at the EIT Health’s Catapult Competition 2018 and granted with a Digital Sandbox Programme 2020.
GlyCardial Diagnostics has also received the support from ENISA (Ministerio de Industria, Comercio y Turismo).
Financiado por FEDER / Ministerio de Ciencia, Innovación y Universidades – Agencia Estatal de Investigación / Proyecto Apo J-Glyc en la isquemia cardiovascular (AGLIC) Expediente RTC-2017-6710-1
Subvencionado por el Centro para el Desarrollo Tecnológico Industrial (CDTI) (Referencia Proyecto: SNEO-20181107)
Ayudas de la OEPM para el fomento de solicitudes de patentes y modelos de utilidad 2019.